TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $45
Needham Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $60
TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
TD Cowen Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
William Blair Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $52
Morgan Stanley Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)
Needham Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $60
Ionis Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $77
Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $64
Wells Fargo Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
Promising Potential of Ionis Pharmaceuticals' Pelacarsen Drives Buy Rating Amidst Phase 3 HORIZON Trial Optimism
TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
TD Cowen Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals Analyst Ratings
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target
UBS Initiates Ionis Pharmaceuticals(IONS.US) With Hold Rating, Announces Target Price $45
Ionis Pharmaceuticals Price Target Cut to $45.00/Share From $47.00 by JP Morgan